Interim Results of First-Ever Global Survey Show People with Type 2 Diabetes Underestimate their Cardiovascular Risk
- Globally, cardiovascular disease (CVD) is the most common cause of death in people with type 2 diabetes[1]
- 1 in 3 respondents considered themselves to be at low risk of CVD[2]
- 1 in 6 respondents had never discussed type 2 diabetes and cardiovascular risk with a healthcare professional[2]
- The Taking Diabetes to Heart global online survey for people with type 2 diabetes was presented at the IDF Congress 2cardiovascular risk17 in Abu Dhabi
- 1 in 3 respondents considered themselves to be at low risk of CVD[2]
- 1 in 6 respondents had never discussed type 2 diabetes and cardiovascular risk with a healthcare professional[2]
- The Taking Diabetes to Heart global online survey for people with type 2 diabetes was presented at the IDF Congress 2cardiovascular risk17 in Abu Dhabi
Today the International Diabetes Federation (IDF) presented the interim results of the first ever multi-country online survey on CVD risk awareness and knowledge among people living with type 2 diabetes, indicating low levels of awareness and limited dialogue between patients and healthcare professionals. The global survey - Taking Diabetes to Heart - developed in partnership with Novo Nordisk, runs until March 2cardiovascular risk18 and is open to all people with type 2 diabetes.
Diabetes currently affects 425 million adults worldwide[1], with most cases being type 2 diabetes. Cardiovascular disease, which includes stroke, coronary heart disease and peripheral artery disease[3], is the leading cause of disability and death in people with type 2 diabetes[1],[4].
To date, 943 responses to the survey have been received from 32 countries and interim findings show that:
- 1 in 3 respondents living with type 2 diabetes consider their risk of CVD to below[2]
- 26% of respondents had either never learned about CVD or received information on CVD several years following their type 2 diabetes diagnosis[2]
- 1 in 6 respondents had never discussed their type 2 diabetes and CVD risk with a healthcare professional[2]
- 26% of respondents had either never learned about CVD or received information on CVD several years following their type 2 diabetes diagnosis[2]
- 1 in 6 respondents had never discussed their type 2 diabetes and CVD risk with a healthcare professional[2]
"The interim results of Taking Diabetes to Heart reiterate the importance of raising awareness of the association between type 2 diabetes and cardiovascular disease to promote prevention, timely diagnosis and appropriate treatment to help reduce the current burden that the two conditions represent," said Dr Shaukat Sadikot, outgoing IDF President. "With the world facing an increase in the prevalence of type 2 diabetes, better understanding the link between these conditions is needed more than ever."
Taking Diabetes to Heart - http://www.idf.org/takingdiabetes2heart/survey - aims to gather insights on current gaps in education and CVD risk behaviour among people with type 2 diabetes, and to put in place advocacy and patient support strategies and tactics to improve health and wellbeing among populations.
"Cardiovascular disease is the leading cause of disability and death among people living with type 2 diabetes. Too few individuals with diabetes are being informed by healthcare professionals of their cardiovascular risk and the impact that risk may have on their longevity and quality of life," said Alan Moses, senior vice president and chief medical officer of Novo Nordisk. "We encourage more people in the diabetes community to complete the Taking Diabetes to Heart survey to strengthen the global findings that will inform future efforts to help improve outcomes."
The results of Taking Diabetes to Heart will serve to define the actions that are required to improve the health outcomes of people with type 2 diabetes. The initiative will culminate in a comprehensive report with country-specific results and resources to help support knowledge and awareness of CVD among people with type 2 diabetes around the world.
For more information about Taking Diabetes to Heart, visit http://www.idf.org/takingdiabetes2heart. For more information about diabetes and CVD, visit http://www.idf.org/cvd
About the International Diabetes Federation
The International Diabetes Federation (IDF) is an umbrella organisation of over 23cardiovascular risk national diabetes associations in 165 countries and territories. It represents the interests of the growing number of people with diabetes and those at risk. The Federation has been leading the global diabetes community since 195cardiovascular risk. The Federation's activities aim to influence policy, increase public awareness and encourage health improvement, promote the exchange of high-quality information about diabetes, and provide education for people with diabetes and their healthcare providers. IDF is associated with the Department of Public Information of the United Nations and is in official relations with the World Health Organization (WHO). http://www.idf.org.
About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 9cardiovascular risk years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,7cardiovascular riskcardiovascular risk people in 77 countries and markets its products in more than 165 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Taking Diabetes to Heart
Taking Diabetes to Heart - http://www.idf.org/takingdiabetes2heart - consists of an online survey available in multiple languages, including Arabic, Bulgarian, Chinese, Danish, Dutch, English, French, Filipino, Finnish, German, Hindi, Italian, Portuguese, Russian, Spanish, Swahili and Vietnamese. The survey will remain online until March 2cardiovascular risk18. Results from the survey will be used to inform policy and decision-making around this common and serious complication of diabetes.[2],[3]
Further information
Media:
Katrine Sperling +45 4442 6718 krsp@novonordisk.com
Asa Josefsson +45 3cardiovascular risk79 77cardiovascular risk8 aajf@novonordisk.com
Investors:
Peter Hugreffe Ankersen +45 3cardiovascular risk75 9cardiovascular risk85 phak@novonordisk.com
Hanna Ogren +45 3cardiovascular risk79 8519 haoe@novonordisk.com
Anders Mikkelsen +45 3cardiovascular risk79 4461 armk@novonordisk.com
Christina Kjaer +45 3cardiovascular risk79 3cardiovascular riskcardiovascular risk9 cnje@novonordisk.com
Kasper Veje (US) +1 6cardiovascular risk9 235 8567 kpvj@novonordisk.com
IDF Media:
Lorenzo Piemonte +32 495 797 936 lorenzo.piemonte@idf.org
Suvi Karuranga +32 267 955 88 suvi.karuranga@idf.org
References
1. International Diabetes Federation. IDF Diabetes Atlas, 8th Edition. Brussels, Belgium: International Diabetes Federation, 2cardiovascular risk17. Available at: http://www.diabetesatlas.org
2. International Diabetes Federation, 2cardiovascular risk17. Taking Diabetes to Heart - Global IDF survey on CVD risk awareness among people with diabetes. Available at: http://www.idf.org/takingdiabetes2heart
3. International Diabetes Federation. Diabetes and Cardiovascular Disease. Brussels, Belgium: International Diabetes Federation, 2cardiovascular risk16. Available at: http://www.idf.org/cvd
4. World Health Organization, editor. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva, Switzerland: World Health Organization; 2cardiovascular riskcardiovascular risk9. 62p.
Source: Novo Nordisk
Katrine Sperling +45 4442 6718 krsp@novonordisk.com
Asa Josefsson +45 3cardiovascular risk79 77cardiovascular risk8 aajf@novonordisk.com
Investors:
Peter Hugreffe Ankersen +45 3cardiovascular risk75 9cardiovascular risk85 phak@novonordisk.com
Hanna Ogren +45 3cardiovascular risk79 8519 haoe@novonordisk.com
Anders Mikkelsen +45 3cardiovascular risk79 4461 armk@novonordisk.com
Christina Kjaer +45 3cardiovascular risk79 3cardiovascular riskcardiovascular risk9 cnje@novonordisk.com
Kasper Veje (US) +1 6cardiovascular risk9 235 8567 kpvj@novonordisk.com
IDF Media:
Lorenzo Piemonte +32 495 797 936 lorenzo.piemonte@idf.org
Suvi Karuranga +32 267 955 88 suvi.karuranga@idf.org
References
1. International Diabetes Federation. IDF Diabetes Atlas, 8th Edition. Brussels, Belgium: International Diabetes Federation, 2cardiovascular risk17. Available at: http://www.diabetesatlas.org
2. International Diabetes Federation, 2cardiovascular risk17. Taking Diabetes to Heart - Global IDF survey on CVD risk awareness among people with diabetes. Available at: http://www.idf.org/takingdiabetes2heart
3. International Diabetes Federation. Diabetes and Cardiovascular Disease. Brussels, Belgium: International Diabetes Federation, 2cardiovascular risk16. Available at: http://www.idf.org/cvd
4. World Health Organization, editor. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva, Switzerland: World Health Organization; 2cardiovascular riskcardiovascular risk9. 62p.
Source: Novo Nordisk
ข่าวcardiovascular risk+Type 2 Diabetesวันนี้
Ozempic(R) Consistently Reduced the Risk of Major Cardiovascular Events Across Type 2 Diabetes Populations at High CV Risk Regardless of Prior CV Events at Baseline
Ozempic(R) (semaglutide) consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack, non-fatal stroke or cardiovascular death (collectively termed major adverse cardiovascular events, MACE) in people with type 2 diabetes at high cardiovascular risk regardless of previously having had a cardiovascular event at the start of the trial.1 Findings from two post-hoc subgroup analyses of the SUSTAIN 6 trial and one post-hoc meta-analysis of MACE in the
Interim Results of First-Ever Global Survey Show People with Type 2 Diabetes Underestimate their Cardiovascular Risk
- Globally, cardiovascular disease (CVD) is the most common cause of death in people with type 2 diabetes[1] - 1 in 3 respondents considered themselves to be at low risk of CVD[2] - 1...Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial
Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major...American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and established cardiovascular disease in new Expert Consensus Decision Pathway
A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends...
Latest state-of-the-art health check-up technology comes to Thailand
—
Verita Health MahaNakhon (VMH) is introducing "Verita Wisdom", a new 360° state-of-...